Patents strengthen global IP position around next-generation immunotherapies

Silicon Valley, California – December 2025 | Gritstone Bio, Inc., a biotechnology company developing next-generation immunotherapies targeting tumor-specific peptide–HLA (pMHC) complexes, today announced the issuance of two patents in 2025 expanding the company’s international intellectual property portfolio.

The newly granted patents include:

• Israeli Patent No. 280890, issued September 2, 2025, which covers isolated antigen-binding proteins (ABPs) that specifically recognize defined human leukocyte antigen (HLA)–peptide complexes.
• Chinese Patent No. ZL201980060989.6, issued October 28, 2025, which claims ABPs directed to HLA class I–restricted peptide targets and includes broad protection for their therapeutic, diagnostic, and cellular engineering applications.

Both patents strengthen Gritstone’s foundational IP around targeting intracellular antigens presented on HLA molecules, a central pillar of the company’s therapeutic platforms.

The patents cover isolated antigen-binding proteins and related constructs that bind specific HLA-peptide complexes, including variants, fragments, vectors, engineered cells, and pharmaceutical compositions. The issued claims also encompass applications in CAR-T constructs, multispecific formats, and engineered immune cells, supporting Gritstone’s development across both biologics and cellular therapy platforms.

With these issuances, Gritstone continues to expand its IP protection across North America, Europe, and Asia to support development of novel immunotherapies that leverage the unique biology of pMHC targets.

Media Contact:
Rachel Miller
VP of Operations
Gritstone Bio
rmiller@gritstone.com

Media Contact:
Dan Budwick
1AB Media
dan@1abmedia.com